Literature DB >> 3918688

Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.

P J Prichard, D Rubinstein, D B Jones, F J Dudley, R A Smallwood, W J Louis, N D Yeomans.   

Abstract

Healing of duodenal ulcers was assessed in 66 patients who received omeprazole either 10 mg or 30 mg daily for four weeks in a double blind study. Healing was rapid in both groups. At two weeks the ulcers in 15 of the 30 patients taking 10 mg daily had healed compared with 28 of the 36 (78%) taking 30 mg daily (p less than 0.03). At four weeks the respective proportions had risen to 83% (25/30) and 94% (33/35) (p greater than 0.05). In non-smokers the proportion of ulcers healed did not differ significantly with the two doses, although there was a trend for less healing at two weeks with 10 mg daily; in smokers significantly fewer ulcers (p less than 0.05) were healed with 10 mg than 30 mg daily at two weeks (7/16 (44%) v 17/21 (81%] and at four weeks (12/16 (75%) v all 21 (100%]. Adverse reactions were few and transient and were considered unlikely to be due to omeprazole.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918688      PMCID: PMC1417300          DOI: 10.1136/bmj.290.6468.601

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  4 in total

1.  Antrectomy and maximal acid output.

Authors:  S K Lam
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

2.  Influence of cigarette smoking on healing and relapse in duodenal ulcer disease.

Authors:  M G Korman; J Hansky; E R Eaves; G T Schmidt
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

3.  Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.

Authors:  S Gustavsson; H O Adami; L Lööf; A Nyberg; O Nyrén
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

4.  Characterization of gastric mucosal membranes. X. Immunological studies of gastric (H+ + K+)-ATPase.

Authors:  G Saccomani; H F Helander; S Crago; H H Chang; D W Dailey; G Sachs
Journal:  J Cell Biol       Date:  1979-11       Impact factor: 10.539

  4 in total
  10 in total

1.  Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial. Cooperative study group.

Authors: 
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

Review 2.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

3.  Omeprazole versus placebo in duodenal ulcer healing. The United States experience.

Authors:  D Y Graham; A McCullough; M Sklar; S J Sontag; W M Roufail; R C Stone; R H Bishop; N Gitlin; A J Cagliola; R S Berman
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

Review 4.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 5.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

6.  Oral phenytoin pharmacokinetics during omeprazole therapy.

Authors:  P J Prichard; R P Walt; G K Kitchingman; K W Somerville; M J Langman; J Williams; A Richens
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

7.  Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing.

Authors:  M Hongo; S Ohara; Y Hirasawa; S Abe; S Asaki; T Toyota
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

8.  Comparative tolerability profile of omeprazole in clinical trials.

Authors:  T J Simon; D C Bradstreet
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

9.  Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.

Authors:  V Savarino; G S Mela; P Zentilin; P Cutela; M R Mele; S Vigneri; G Celle
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

10.  Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients.

Authors:  E G Hewson; N D Yeomans; P W Angus; A Shulkes; C W Brook; R B Sewell; R A Smallwood
Journal:  Gut       Date:  1988-12       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.